.gif)
Eisai Pharmaceuticals India Pvt. Ltd announced that Eisai Pharmatechnology and Manufacturing Pvt. Ltd. and Eisai Pharmaceuticals India Pvt. Ltd. two subsidiaries of Eisai Co. Ltd, have been amalgamated and the new entity shall be known as “Eisai Pharmaceuticals India Pvt. Ltd”. The amalgamation of the two subsidiaries was completed to leverage the capability of Eisai India’s state-of-the art integrated research and manufacturing operations with its specialized sales force to meet its business objectives in India. This also provides a more rationalized structure for better efficiency.
Dr. Sanjit Singh Lamba has been appointed as the Managing Director of Eisai Pharmaceuticals India Pvt. Ltd., the merged entity. Eisai Co., Ltd, a global R&D based pharmaceutical company. In line with its human health care (hhc) mission, Eisai is committed to improving global access to medicines (ATM) over the medium- to long-term through partnership strategies that involve working with governments, international organizations, private entities and non-profit organizations.
Eisai, since launching its anti-Alzheimer's agent Aricept® (brand name in India: Aricep®) and proton pump inhibitor Pariet® (brand name in India: Parit™) in India in 2005, has been providing both drugs to patients at affordable prices. Halaven® (eribulinmesylate), a novel anticancer agent discovered and developed in-house by Eisai, is currently approved in more than 50 countries, including Japan, the United States and Europe. Halaven was approved in India in April 2013 for the treatment of locally advanced or metastatic breast cancer.
As part of the “HOPE TO HER” Patient Assistance Program (PAP), Eisai India introduced a tiered-pricing model for Halaven in which the cost burden to patients is differentiated according to income level, ranging from full payment by the patient to total reimbursement by Eisai.
As part of its commitment to this global initiative, Eisai has agreed to supply 2.2 billion diethylcarbamazine citrate (DEC) 100 mg tablets free of charge to the World Health Organization (WHO) under the Mass Drug Administration (MDA) program for eliminating lymphatic filariasis.
